448 related articles for article (PubMed ID: 10075594)
21. Basiliximab: efficacy and tolerability in adults and children.
Mocarquer A; Pinto V; Buckel E; Lagos E; Pefaur J; Ramirez K; Morales J; Rosatti P; Elberg A;
Transplant Proc; 2003 Nov; 35(7):2518-9. PubMed ID: 14612000
[TBL] [Abstract][Full Text] [Related]
22. Basiliximab: a review of its use as induction therapy in renal transplantation.
McKeage K; McCormack PL
BioDrugs; 2010 Feb; 24(1):55-76. PubMed ID: 20055533
[TBL] [Abstract][Full Text] [Related]
23. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
24. Screening for basiliximab exposure-response relationships in renal allotransplantation.
Kovarik JM; Moore R; Wolf P; Abendroth D; Landsberg D; Soulillou JP; Gerbeau C; Schmidt AG
Clin Transplant; 1999 Feb; 13(1 Pt 1):32-8. PubMed ID: 10081632
[TBL] [Abstract][Full Text] [Related]
25. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
[TBL] [Abstract][Full Text] [Related]
26. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
Tan J; Yang S; Wu W
Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
[TBL] [Abstract][Full Text] [Related]
27. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.
Mehra MR; Zucker MJ; Wagoner L; Michler R; Boehmer J; Kovarik J; Vasquez A
J Heart Lung Transplant; 2005 Sep; 24(9):1297-304. PubMed ID: 16143248
[TBL] [Abstract][Full Text] [Related]
28. Use of simulect can reduce the incidence of acute rejection and demonstrates with superior 3-year patient and graft survival rates in renal transplantation.
Chu SH; Chiang YJ; Huang CC; Lee PH; Hu RH; Lai MK; Chueh SC; Tsai MK
Transplant Proc; 2004 Sep; 36(7):2108-9. PubMed ID: 15518763
[TBL] [Abstract][Full Text] [Related]
29. Use of basiliximab with mycophenolate mofetil in kidney transplantation.
Baron PW; Weissman J; Ojogho ON; Sahney S; Cutler D; James S; Oculam C; Abdelhalim F; Nehlsen-Cannarella SL; Teichman S; Concepcion W
Transplant Proc; 2003 Dec; 35(8):2881-4. PubMed ID: 14697927
[TBL] [Abstract][Full Text] [Related]
30. Basiliximab induction in renal transplantation: long-term outcome.
Atlani M; Sharma RK; Gupta A
Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
[TBL] [Abstract][Full Text] [Related]
31. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial.
Sheashaa HA; Bakr MA; Ismail AM; Sobh MA; Ghoneim MA
J Nephrol; 2003; 16(3):393-8. PubMed ID: 12832740
[TBL] [Abstract][Full Text] [Related]
32. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
33. Economic analysis of basiliximab in renal transplantation.
Keown PA; Balshaw R; Krueger H; Baladi JF
Transplantation; 2001 Jun; 71(11):1573-9. PubMed ID: 11435967
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group.
Kovarik JM; Kahan BD; Rajagopalan PR; Bennett W; Mulloy LL; Gerbeau C; Hall ML
Transplantation; 1999 Nov; 68(9):1288-94. PubMed ID: 10573065
[TBL] [Abstract][Full Text] [Related]
36. Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation.
Rivera CF; Hernández AA; Verdejo PV; García JO; Rego SC; Cañedo FV
Transplant Proc; 2005 Nov; 37(9):3733-5. PubMed ID: 16386521
[TBL] [Abstract][Full Text] [Related]
37. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
[TBL] [Abstract][Full Text] [Related]
38. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
39. A benefit-risk assessment of basiliximab in renal transplantation.
Boggi U; Danesi R; Vistoli F; Del Chiaro M; Signori S; Marchetti P; Del Tacca M; Mosca F
Drug Saf; 2004; 27(2):91-106. PubMed ID: 14717621
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A
Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
